SAB Biotherapeutics closes USD 85 million follow-on stock offering

SAB Biotherapeutics Inc Ordinary Shares

SAB Biotherapeutics Inc Ordinary Shares

SABS

0.00
  • SAB Bio closed an underwritten public offering of 19.32 million common shares priced at USD 3.85 per share.
  • The offering also included pre-funded warrants for up to 2.75 million shares priced at USD 3.85 per warrant.
  • Gross proceeds were approximately USD 85 million.
  • Net proceeds are intended primarily to support development of SAB-142 and related manufacturing and regulatory activities.
  • Underwriters have a 30-day option to purchase up to 3.31 million additional shares on the same terms.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. SAB Biotherapeutics Inc. published the original content used to generate this news brief on March 19, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.